Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039134 | 0.85 | MCOLN3 (0.55) | KMT2AUSP2GAASMN1; SMN2MEN1 | |
| SCHEMBL12180426 | 0.82 | SMN1; SMN2 (0.67) | KMT2AUSP2GAASMN1; SMN2MEN1 | |
| SCHEMBL5943967 | 0.81 | L3MBTL1 (0.64) | KMT2AGAASMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL13290942 | 0.81 | KMT2A (0.60) | KMT2AUSP2GAASMN1; SMN2MEN1 | |
| SCHEMBL31536845 | 0.81 | KMT2A (0.60) | KMT2AUSP2GAASMN1; SMN2MEN1 | |
| SCHEMBL5188196 | 0.81 | KMT2A (0.60) | KMT2AUSP2GAASMN1; SMN2MEN1 | |
| SCHEMBL739940 | 0.81 | KMT2A (0.60) | KMT2AUSP2GAASMN1; SMN2MEN1 | |
| SCHEMBL1066283 | 0.81 | KMT2A (0.60) | KMT2AUSP2GAASMN1; SMN2MEN1 | |
| SCHEMBL12933048 | 0.79 | KMT2A (0.58) | KMT2AUSP2GAASMN1; SMN2MEN1 | |
| SCHEMBL6038929 | 0.79 | ALDH1A1 (0.58) | KMT2AUSP2GAASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | KMT2A 4190/4885USP2 4477/4885GAA 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.